Cargando…

Baseline interleukin‐10, CD163, and tumor necrosis factor‐like weak inducer of apoptosis (TWEAK) gingival tissue levels in relation to clinical periodontal treatment outcomes: A 12‐week follow‐up study

BACKGROUND: The aim of this study was to examine the relationship between healing response after non‐surgical periodontal treatment and baseline gingival tissue levels of M2 macrophage activation‐related proteins CD163, interleukin (IL)‐10, interferon (IFN)‐γ, and tumor necrosis factor‐like weak ind...

Descripción completa

Detalles Bibliográficos
Autores principales: Yilmaz, Mustafa, Demir, Esra, Gürsoy, Mervi, Firatli, Erhan, Gürsoy, Ulvi Kahraman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087717/
https://www.ncbi.nlm.nih.gov/pubmed/35819128
http://dx.doi.org/10.1002/JPER.22-0242
_version_ 1785022413497434112
author Yilmaz, Mustafa
Demir, Esra
Gürsoy, Mervi
Firatli, Erhan
Gürsoy, Ulvi Kahraman
author_facet Yilmaz, Mustafa
Demir, Esra
Gürsoy, Mervi
Firatli, Erhan
Gürsoy, Ulvi Kahraman
author_sort Yilmaz, Mustafa
collection PubMed
description BACKGROUND: The aim of this study was to examine the relationship between healing response after non‐surgical periodontal treatment and baseline gingival tissue levels of M2 macrophage activation‐related proteins CD163, interleukin (IL)‐10, interferon (IFN)‐γ, and tumor necrosis factor‐like weak inducer of apoptosis (TWEAK), and the CD163/TWEAK ratio. METHODS: Eighty‐eight gingival tissue samples from 44 Stage III/IV, Grade C periodontitis patients (18 smokers) and 41 tissue samples from 41 periodontally healthy participants (18 smokers) were evaluated. Clinical parameters were recorded in periodontally healthy individuals at baseline and in periodontitis patients at pre‐treatment and 2, 6, and 12 weeks following therapy. IL‐10, IFN‐γ, CD163, and TWEAK levels were analyzed with Luminex technique. RESULTS: Tissue levels (median, 1(st)–3(rd) quartile) of IL‐10 (pg/ng protein), CD163 (pg/μg protein) and TWEAK (pg/μg protein) were as follows: IL‐10 periodontitis: 2.08, 0.86–5.32 and periodontally healthy: 5.22, 3.20–10.25; CD163 periodontitis: 8.85, 4.92–14.06 and periodontally healthy: 18.36, 12.51‐34.02; TWEAK periodontitis: 0.08, 0.05–0.11 and periodontally healthy: 0.16, 0.12–0.21. IL‐10, CD163, and TWEAK levels were higher (P < 0.001) in periodontally healthy tissues than in periodontitis tissues. Pocket closure at 12 weeks was associated with elevated baseline gingival CD163 levels (P = 0.047) and CD163/TWEAK ratio (P = 0.001). Elevated baseline gingival CD163/TWEAK ratio was associated with pocket reduction at 6 (P = 0.022) and 12 weeks (P = 0.002). CONCLUSION: Associations of pocket closure with pre‐treatment gingival tissue CD163 levels and CD163/TWEAK ratio indicate that baseline M2 macrophage activation profile may play a role in periodontal wound healing.
format Online
Article
Text
id pubmed-10087717
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-100877172023-04-12 Baseline interleukin‐10, CD163, and tumor necrosis factor‐like weak inducer of apoptosis (TWEAK) gingival tissue levels in relation to clinical periodontal treatment outcomes: A 12‐week follow‐up study Yilmaz, Mustafa Demir, Esra Gürsoy, Mervi Firatli, Erhan Gürsoy, Ulvi Kahraman J Periodontol Discovery Science BACKGROUND: The aim of this study was to examine the relationship between healing response after non‐surgical periodontal treatment and baseline gingival tissue levels of M2 macrophage activation‐related proteins CD163, interleukin (IL)‐10, interferon (IFN)‐γ, and tumor necrosis factor‐like weak inducer of apoptosis (TWEAK), and the CD163/TWEAK ratio. METHODS: Eighty‐eight gingival tissue samples from 44 Stage III/IV, Grade C periodontitis patients (18 smokers) and 41 tissue samples from 41 periodontally healthy participants (18 smokers) were evaluated. Clinical parameters were recorded in periodontally healthy individuals at baseline and in periodontitis patients at pre‐treatment and 2, 6, and 12 weeks following therapy. IL‐10, IFN‐γ, CD163, and TWEAK levels were analyzed with Luminex technique. RESULTS: Tissue levels (median, 1(st)–3(rd) quartile) of IL‐10 (pg/ng protein), CD163 (pg/μg protein) and TWEAK (pg/μg protein) were as follows: IL‐10 periodontitis: 2.08, 0.86–5.32 and periodontally healthy: 5.22, 3.20–10.25; CD163 periodontitis: 8.85, 4.92–14.06 and periodontally healthy: 18.36, 12.51‐34.02; TWEAK periodontitis: 0.08, 0.05–0.11 and periodontally healthy: 0.16, 0.12–0.21. IL‐10, CD163, and TWEAK levels were higher (P < 0.001) in periodontally healthy tissues than in periodontitis tissues. Pocket closure at 12 weeks was associated with elevated baseline gingival CD163 levels (P = 0.047) and CD163/TWEAK ratio (P = 0.001). Elevated baseline gingival CD163/TWEAK ratio was associated with pocket reduction at 6 (P = 0.022) and 12 weeks (P = 0.002). CONCLUSION: Associations of pocket closure with pre‐treatment gingival tissue CD163 levels and CD163/TWEAK ratio indicate that baseline M2 macrophage activation profile may play a role in periodontal wound healing. John Wiley and Sons Inc. 2022-08-17 2023-01 /pmc/articles/PMC10087717/ /pubmed/35819128 http://dx.doi.org/10.1002/JPER.22-0242 Text en © 2022 The Authors. Journal of Periodontology published by Wiley Periodicals LLC on behalf of American Academy of Periodontology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Discovery Science
Yilmaz, Mustafa
Demir, Esra
Gürsoy, Mervi
Firatli, Erhan
Gürsoy, Ulvi Kahraman
Baseline interleukin‐10, CD163, and tumor necrosis factor‐like weak inducer of apoptosis (TWEAK) gingival tissue levels in relation to clinical periodontal treatment outcomes: A 12‐week follow‐up study
title Baseline interleukin‐10, CD163, and tumor necrosis factor‐like weak inducer of apoptosis (TWEAK) gingival tissue levels in relation to clinical periodontal treatment outcomes: A 12‐week follow‐up study
title_full Baseline interleukin‐10, CD163, and tumor necrosis factor‐like weak inducer of apoptosis (TWEAK) gingival tissue levels in relation to clinical periodontal treatment outcomes: A 12‐week follow‐up study
title_fullStr Baseline interleukin‐10, CD163, and tumor necrosis factor‐like weak inducer of apoptosis (TWEAK) gingival tissue levels in relation to clinical periodontal treatment outcomes: A 12‐week follow‐up study
title_full_unstemmed Baseline interleukin‐10, CD163, and tumor necrosis factor‐like weak inducer of apoptosis (TWEAK) gingival tissue levels in relation to clinical periodontal treatment outcomes: A 12‐week follow‐up study
title_short Baseline interleukin‐10, CD163, and tumor necrosis factor‐like weak inducer of apoptosis (TWEAK) gingival tissue levels in relation to clinical periodontal treatment outcomes: A 12‐week follow‐up study
title_sort baseline interleukin‐10, cd163, and tumor necrosis factor‐like weak inducer of apoptosis (tweak) gingival tissue levels in relation to clinical periodontal treatment outcomes: a 12‐week follow‐up study
topic Discovery Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087717/
https://www.ncbi.nlm.nih.gov/pubmed/35819128
http://dx.doi.org/10.1002/JPER.22-0242
work_keys_str_mv AT yilmazmustafa baselineinterleukin10cd163andtumornecrosisfactorlikeweakinducerofapoptosistweakgingivaltissuelevelsinrelationtoclinicalperiodontaltreatmentoutcomesa12weekfollowupstudy
AT demiresra baselineinterleukin10cd163andtumornecrosisfactorlikeweakinducerofapoptosistweakgingivaltissuelevelsinrelationtoclinicalperiodontaltreatmentoutcomesa12weekfollowupstudy
AT gursoymervi baselineinterleukin10cd163andtumornecrosisfactorlikeweakinducerofapoptosistweakgingivaltissuelevelsinrelationtoclinicalperiodontaltreatmentoutcomesa12weekfollowupstudy
AT firatlierhan baselineinterleukin10cd163andtumornecrosisfactorlikeweakinducerofapoptosistweakgingivaltissuelevelsinrelationtoclinicalperiodontaltreatmentoutcomesa12weekfollowupstudy
AT gursoyulvikahraman baselineinterleukin10cd163andtumornecrosisfactorlikeweakinducerofapoptosistweakgingivaltissuelevelsinrelationtoclinicalperiodontaltreatmentoutcomesa12weekfollowupstudy